论文部分内容阅读
目的探讨淋巴结转移比率(MLNR)在预测淋巴结转移乳腺癌患者预后中的应用价值。方法回顾性分析94例接受改良根治术治疗的淋巴结转移乳腺癌患者的临床资料,并对患者生存情况及影响预后的相关因素进行分析。结果 94例患者随访时间为12~75个月,中位随访时间为64个月,5年生存率为72.34%(68/94)。总MLNR为0.31(486/1 553)。单因素分析显示原发肿瘤大小、淋巴结转移数目、ER状态、放疗与否和MLNR影响淋巴结转移乳腺癌患者的预后(P<0.05),而患者年龄、绝经与否、PR状态、内分泌治疗与否和组织学类型与预后无关(P>0.05)。多因素分析发现MLNR(OR=2.565,95%CI=1.043~6.309,P=0.040)和肿瘤大小(OR=2.220,95%CI=1.045~4.716,P=0.038)是影响淋巴结转移乳腺癌患者预后的独立因素。结论 MLNR是影响淋巴结转移乳腺癌患者的独立预后因素,且其预测效果比淋巴结转移数目更为准确和客观。
Objective To investigate the value of lymph node metastasis (MLNR) in predicting the prognosis of patients with lymph node metastatic breast cancer. Methods The clinical data of 94 patients with lymph node metastatic breast cancer undergoing modified radical mastectomy were retrospectively analyzed. The survival and prognostic factors were analyzed. Results 94 patients were followed up for 12 to 75 months with a median follow-up of 64 months and a 5-year survival rate of 72.34% (68/94). Total MLNR was 0.31 (486/1 553). Univariate analysis showed that the primary tumor size, the number of lymph node metastasis, ER status, radiotherapy or not, and MLNR prognosis of patients with lymph node metastasis of breast cancer (P <0.05), and the age of patients, menopause or not, PR status, endocrine therapy or not And histological type and prognosis (P> 0.05). Multivariate analysis showed that MLNR (OR = 2.565,95% CI = 1.043-6.309, P = 0.040) and tumor size (OR = 2.220,95% CI 1.045-4.716, P = 0.038) were the prognostic factors for patients with lymph node metastasis The independent factor. Conclusion MLNR is an independent prognostic factor in patients with lymph node metastasis of breast cancer, and its predictive value is more accurate and objective than the number of lymph node metastases.